Literature DB >> 25480853

Addressing Medicaid/marketplace churn through multimarket plans: assessing the current state of play.

Sara Rosenbaum1.   

Abstract

Both before and after the Affordable Care Act (ACA), the US health insurance system is characterized by fragmentation. Pre-ACA, this fragmentation included major coverage gaps, causing significant periods of coverage interruption, especially for lower-income people. The ACA does not end the problem of churning among sources of public financing, but it does hold the potential for enabling people to move among sources of coverage rather than go without insurance. Several strategies for reducing coverage churn exist, but none is foolproof and all are in their early stages. Thus the ability of issuers to participate across multiple public financing arrangements and to offer stable provider networks becomes crucial to achieving continuity of care. Interviews with nine companies involved in developing or operating multimarket strategies confirm the feasibility of this approach while revealing major challenges, especially the challenge of finding providers willing to treat members regardless of the source of coverage. Strategies for increasing multimarket plans and networks represent one of the great areas of future policy and operational focus.
Copyright © 2015 by Duke University Press.

Entities:  

Keywords:  Medicaid; churn; multimarket plans

Mesh:

Year:  2014        PMID: 25480853     DOI: 10.1215/03616878-2854855

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN: 0361-6878            Impact factor:   2.265


  2 in total

1.  Does Churning in Medicaid Affect Health Care Use?

Authors:  Eric T Roberts; Craig Evan Pollack
Journal:  Med Care       Date:  2016-05       Impact factor: 2.983

2.  Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data.

Authors:  Anem Waheed; Angie Mae Rodday; Anita J Kumar; Kenneth B Miller; Susan K Parsons
Journal:  JCO Clin Cancer Inform       Date:  2022-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.